FDA
-
-
-
-
-
-
-
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
-
-
-
-
-
-
-
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
-
-
-
-
-
-
-
Pfizer, Moderna, BioNTech trade lower amid report of vaccine link to child deaths
-
-
-
-
-
-
-
FDA tightens requirements for COVID vaccine, adding trials for healthy adults
-
-
-
-
-
-
-
Duality Biologics and BioNTech Presented Positive Interim Data for Investigational B7-H3 Antibody-Drug Conjugate BNT324/DB-1311 in Advanced Solid Tumors at the ESMO Asia Congress 2024
-
-
-
-
-
-
-
BioNTech SE (BNTX) Announces Lift of Partial Clinical Hold for BNT326/YL202
-
-
-
-
-
-
-
BioNTech SE (BNTX): FDA has placed partial clinical hold on multicenter, open-label, first-in-human Phase 1 clinical (NCT05653752) trial sponsored by MediLink
-
334,466 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


